GPC2 and neoplasm: Repeated testing of CAR constructs has shown that a CAR composed of a single chain variable fragment (scFv) derived from an antibody that targets GPC2 (CT3) exhibits superior anti-tumor activity against HRNB (Figure 4) (73).